Bidding for Onyx Pharma (ONXX) Done? Not Likely...
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- US stocks close down as oil spikes 12%, job market weakens
- U.S. nonfarm payroll employment unexpectedly falls in February
- Oracle stock falls on report of scrapped Texas data center plans
- Kuwait cuts oil output as storage fills up
- Boeing reportedly nearing 500-aircraft deal with China ahead of Trump visit
- After-hours movers: Marvell, Samsara, GAP, Cooper Cos.
- After-hours movers: Broadcom, StubHub, Cracker Barrel, Grocery Outlet, Veeva Systems and more
- After-hours movers: Moderna, CrowdStrike, Ross Stores, Box and more
- After-hours movers: MongoDB, Credo, SoFi Technologies and more
- After-hours movers: Dell, Block, CoreWeave, Autodesk, MARA and more
Novartis (NVS), Pfizer (PFE) Out on Onyx (ONXX); Is Amgen (AMGN) the Sole Runner?
August 13, 2013 3:23 PM UTCOnyx Pharma (Nasdaq: ONXX) shares dropped down for a second time today on this roller coaster Tuesday.
First, the stock got a boost following comments from Novartis (NYSE: NVS) chairman Joerg Reinhardt, who... More
Brean Capital Boosts Onyx Pharma (ONXX) Price Target to $160
July 1, 2013 2:41 PM UTCBrean Capital today maintained a Buy rating on Onyx Pharmaceuticals (NASDAQ: ONXX) and raised its price target to $160.00 (from $115.00). The change follows news Onyx Pharmaceuticals received an unsolicited bid from Amgen Inc. (Nasdaq: AMGN).
"Our $115... More
Maxim Group Downgrades Onyx Pharmaceuticals (ONXX) to Hold
July 1, 2013 11:18 AM UTCMaxim Group downgraded Onyx Pharmaceuticals (NASDAQ: ONXX) from Buy to Hold.
For an analyst ratings summary and ratings history on Onyx Pharmaceuticals click here. For more ratings news on Onyx Pharmaceuticals click here.
Shares of Onyx Pharmaceuticals closed at $86.82 yesterday, with a 52 week range of $63.00-$101.57.... More
Onyx Pharma (ONXX) Reports $120/Share Bid from Amgen (AMGN); Hires Advisor
July 1, 2013 6:24 AM UTCOnyx Pharmaceuticals, Inc. (NASDAQ: ONXX) today confirmed that it has received and rejected an unsolicited proposal from Amgen Inc. (Nasdaq: AMGN) to acquire all of Onyx's outstanding shares and share equivalents for $120 per share in cash, subject to due diligence and other conditions. The Board of Directors of Onyx had evaluated the proposal made by Amgen with the assistance of its financial and legal advisors and concluded that... More
